About the study medicine
Pfizer is investigating a study medicine, PF-08634404, which is a bispecific antibody that was designed to target both PD-1 and VEGF to potentially block immune checkpoints and inhibit angiogenesis. This dual mechanism has the potential to achieve tumor immunosurveillance, while disrupting vascular support for tumor progression, compared with blocking either target alone in patients with solid tumors.
The study medicine is currently being studied in various cancer types, including lung, colorectal, urothelial, renal, hepatocellular carcinomas, gastric, gastroesophageal junction and esophageal carcinomas, and endometrial cancer.
The Symbiotic clinical trials
Explore Pfizer’s Symbiotic program, which is a series of clinical trials evaluating a novel investigational bispecific antibody that is designed to target both PD-1 and VEGF.
A Phase 1b/2 clinical trial of PF-08634404 as monotherapy and in combination with ipilimumab for your patients with unresectable, locally advanced, or metastatic hepatocellular carcinoma.
A Phase 2/3 clinical trial evaluating PF-08634404 in combination with chemotherapy for your treatment-naïve patients with locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma.
A Phase 1b/2 clinical trial of PF-08634404 in combination with different anticancer agents in your patients with advanced solid tumors. The clinical trial currently includes combinations of PF-08634404 with different antibody drug conjugates (ADCs) in treatment-naive patients with locally advanced or metastatic non-small cell lung cancer without actionable genomic alterations.